Dr. Ahrens-Nicklas works to understand why patients with inherited biochemical disorders often suffer severe, untreatable neurologic and cardiac symptoms. She strives to elucidate the link between biochemistry and network excitability, in order to drive new approaches to therapy.
Can Ficicioglu, MD, PhD, a physician-scientist who is an expert in genetic disorders called inborn errors of metabolism, was appointed by the Pennsylvania Department of Health to a statewide Rare Diseases Advisory Council.
In times of uncertainty, a dose of positive news reminds us that making progress through difficult situations is possible - our Children's Hospital of Philadelphia research community does it every day! Whether it's researchers who push the barriers of current autism diagnoses, an 8-year-old survivor who fought off a shrewd cancer, or physicians who act as policy watchdogs to protect
The Ahrens-Nicklas lab combines translational studies in patients with molecular, biochemical, and electrophysiologic studies working with animal models to develop novel therapies for rare inherited pediatric disorders.
The research objectives of the Ischiropoulos Lab are to elucidate the nitric oxide signaling pathways at the proteome level in the cardiovascular and neuronal systems; define the molecular mechanisms by which nitric oxide signaling regulates metabolic pathways during development and aging; and develop and test novel therapeutics for long-chain fatty acid oxidation disorders.
Fostering the careers of the next generation of scientists who seek to discover causes and potential treatments for the class of disorders known as neurodevelopmental disabilities.
